Highly active antiretroviral therapy and tuberculosis control in Africa: synergies and potential. by Harries, Anthony D et al.
Harries, AD; Hargreaves, NJ; Chimzizi, R; Salaniponi, FM (2002)
Highly active antiretroviral therapy and tuberculosis control in Africa:
synergies and potential. Bulletin of the World Health Organization,
80 (6). pp. 464-9. ISSN 0042-9686
Downloaded from: http://researchonline.lshtm.ac.uk/8901/
DOI:
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
Highly active antiretroviral therapy and tuberculosis control
in Africa: synergies and potential
Anthony D. Harries,1 Nicola J. Hargreaves,2 Rehab Chimzizi,3 & Felix M. Salaniponi4
Abstract HIV/AIDS (human immunodeficiency virus/acquired immunodeficiency syndrome) and TB (tuberculosis) are two of the
world’s major pandemics, the brunt of which falls on sub-Saharan Africa. Efforts aimed at controlling HIV/AIDS have largely focused on
prevention, little attention having been paid to care. Work on TB control has concentrated on case detection and treatment. HIV
infection has complicated the control of tuberculosis. There is unlikely to be a decline in the number of cases of TB unless additional
strategies are developed to control both this disease and HIV simultaneously. Such strategies would include active case-finding in
situations where TB transmission is high, the provision of a package of care for HIV-related illness, and the application of highly active
antiretroviral therapy. The latter is likely to have the greatest impact, but for this therapy to become more accessible in Africa the drugs
would have to be made available through international support and a programme structure would have to be developed for its
administration. It could be delivered by means of a structure based on the five-point strategy called DOTS, which has been adopted for
TB control. However, it may be unrealistic to give TB control programmes the responsibility for running such a programme. A better
approach might be to deliver highly active antiretroviral therapy within a comprehensive HIV/AIDS management strategy
complementing the preventive work already being undertaken by AIDS control programmes. TB programmes could contribute towards
the development and implementation of this strategy.
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Introduction
Human immunodeficiency virus/acquired immunodeficiency
syndrome (HIV/AIDS) is the modern world’s principal
pandemic. It has claimed 22 million lives and created
13 million orphans (1). Sub-Saharan Africa bears the brunt
of the catastrophe. In this region with less than 10% of the
world’s population there are 25.3 million people with HIV/
AIDS, i.e. 70% of all cases globally. In 2000 there were
3.8 million new HIV infections in sub-Saharan Africa and
2.4 million people with HIV/AIDS died, representing 80% of
all deaths attributable to AIDS.
AIDS kills young adults in their most productive years,
depriving the region of the skills and knowledge that are
essential for economic development. Because of AIDS, large
numbers of children have to be brought up by their
grandparents. Many orphans cannot attend school, suffer
from poverty and malnutrition, and are drawn into crime,
violence, and commercial sex. AIDS retards development and
may create conditions conducive to political instability.
In 1999 there were estimated to be 8.4 million new cases
of TB in the world (2). Sub-Saharan Africa is the region most
severely affected by this disease (3). HIV fuels the tuberculosis
(TB) epidemic: nearly three-quarters of people infected with
both HIV and Mycobaterium tuberculosis live in sub-Saharan
Africa (3). WHO predicts that by 2005 there will be 3.4 million
TB cases in Africa (2).
Efforts to control HIV/AIDS and TB in
sub-Saharan Africa
HIV/AIDS control efforts
Control efforts have largely centred on prevention. Strategies
for reducing the sexual transmission of HIV have focused on
condom usage, treating sexually transmitted infections, and
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reducing unsafe sexual behaviour. In hospitals, donated blood
is screened for HIV, reducing but not eliminating the risk of
transmitting HIV during transfusions (4).
Voluntary counselling and HIV testing have been
advocated as a golden opportunity for educating and bringing
about behavioural change. However, nearly 90% of infected
people in Africa do not know their HIV serostatus (5). Among
the many reasons for this are a general shortage of accessible
voluntary counselling and HIV testing services, counselling of
poor quality, poor uptake of voluntary counselling and HIV
testing, and denial of the HIV/AIDS problem by both
individuals and communities. Until now there has been a lack
of understanding among policy-makers and health care
providers that voluntary counselling and HIV testing and
prevention should be linked to care. For the majority of people
with HIV-related disease in Africa, only poor-quality clinical
care and inadequate resources are available for treating serious
opportunistic infections and tumours, e.g. Kaposi’s sarcoma.
There is almost no routine use of prophylaxis against
opportunistic infections and virtually no access to antiretroviral
drugs. Thus there is little incentive for people to ask for their
HIV serostatus to be determined.
The aspect of care most likely to benefit an individual
with HIV/AIDS is highly active antiretroviral therapy
(HAART). Furthermore, there is evidence that lowering the
viral load with HAART may reduce the likelihood of
transmitting HIV to others (6). In industrialized countries,
HAART has dramatically improved the survival of patients
living with HIV/AIDS. Indeed, it has transformed AIDS from
a fatal disease into a potentially treatable and chronic condition.
HAART is the standard care for all patients with HIV-related
disease in these countries. In contrast, only some 25 000 of
Africa’s 25 million HIV-positive individuals receive antire-
troviral therapy of any kind. Many of these patients receive the
drugs in a chaotic and unregulatedmanner in the private sector,
with grave implications for the rapid development of drug
resistance (7). The main reasons given for lack of availability of
this therapy have been the high cost of the drugs and the
perceived inability of the health infrastructure in Africa to
manage the complexities of HAART.
TB control efforts
Control efforts have centred on case detection and treatment.
The strategy is simple. Standardized combination chemother-
apy is provided at least to all patients with smear-positive
pulmonary TB. This treatment cures the disease and aims to
prevent further transmission of infection. The targets for
control include curing 85% of detected new smear-positive
cases of pulmonary TB and detecting 70%of existing cases (8).
The success of this strategy depends on the implementa-
tion of a control policy known as DOTS. DOTS is a five-point
package (Box 1) associated with various key operations (9).
Despite the poor health infrastructure in Africa, 55% of the
population is covered by DOTS, 60% of TB cases notified are
treated under a DOTS programme, and 63% of such cases
successfully complete treatment. However, the implementa-
tion of a good DOTS programme is not easy and requires
adequate funding and human resources (10).
Negative effects of HIV on TB control efforts
HIV infection of TB patients adds to the difficulties
encountered in programmes trying to implement the DOTS
strategy (Box 2). The large increase in the number of cases of
TB during the last 15 years has created a need for more staff,
drugs, and resources. Where patients are hospitalized for the
initial phase of treatment, TB wards have become over-
crowded. This has forced the decentralization of treatment to
peripheral health centres and the community. Decentraliza-
tion, although patient-friendly, complicates the logistics of
observing drug administration and maintaining the security of
anti-TB drugs (especially of rifampicin, which is known by
communities to be a useful drug for treating cough, diarrhoea,
and sexually transmitted infections). The supervision and
monitoring of TB control activities also becomes more
difficult and demanding with a decentralized approach. HIV-
positive TB patients experience many HIV-related illnesses
during treatment. They also experience an increased frequency
of adverse drug reactions leading to interruptions of treatment
and occasional fatalities (11). Mortality rates have risen: 20–
30% of HIV-positive smear-positive pulmonary TB patients
die before the end of treatment (11). Even higher mortality
rates are observed in patients with smear-negative TB (12).
Recurrence rates of TB have increased (11), adding to the large
number of new patients presenting annually for treatment.
Health care workers also experience considerable morbidity
and mortality attributable to AIDS, and this in turn
compromises the quality of health care delivery.
African countries with good DOTS programmes
continue to have escalating notifications of TB cases in the
face of high HIV infection rates (13). DOTS alone may not be
sufficient to control TB in areas of epidemic HIV infection:
additional strategies may be needed (14).
Interventions to control TB and HIV
Various additional interventions may help to control TB and
HIV concomitantly (Box 3).Where TB transmission is likely to
be high, e.g. in prisons, boarding schools, health care
institutions and households of diagnosed TB patients, active
rather than passive case-finding may be better for rapid case
detection. Access to specific interventions targeted at HIV-
related diseases requires knowledge of the individual’s HIV
serostatus. This is best achieved through voluntary counselling
and HIV testing sites, which can either be free-standing and
providing a service to the general population or integrated into
the general health care service and providing a service to the
sick. Same-day HIV testing, especially by means of rapid
whole-blood finger-prick kits, facilitates voluntary counselling
and HIV testing and allows quick referral to other support
Box 1. DOTS: a five-point tuberculosis (TB) control
policy package
The package contains the following components:
1. Sustained government and political commitment.
2. Case detection through passive case-finding by ensuring access to
high-quality TB sputum microscopy.
3. Administration of standardized short-course chemotherapy to all
cases of TB under proper conditions of case management, including
direct observation of therapy.
4. An uninterrupted supply of drugs of assured high quality, with
reliable drug procurement and distribution systems.
5. A recording and reporting system permitting assessment of the
outcome of each patient and of overall programme performance.
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services. A package of care is required which includes a two-
way referral system between health facilities and the commu-
nity. This package involves psychosocial support, screening for
sexually transmitted infections and TB, clinical care for
opportunistic infections, palliative care for terminal illness,
prevention of mother-to-child transmission of HIV, home-
based care, preventive therapy, and the possibility of using
antiretroviral drugs.
In Africa, preventive therapy for HIV-related infections
in general and for HIV-related TB is currently based on
cotrimoxazole and isoniazid, respectively. In Coˆte d’Ivoire,
cotrimoxazole significantly reduced the case-fatality rate in
HIV-positive TB patients (15) and reduced morbidity in HIV-
infected patients without TB (16). The Joint United Nations
Programme on HIV/AIDS has therefore provisionally
recommended that cotrimoxazole be given to all patients in
Africa living with AIDS, which, by definition, includes HIV-
positive patients with TB (17). However, it would be prudent
to gather more evidence about the efficacy of this intervention
because of different patterns of disease and differing drug-
resistance profiles in other parts of the region. Even if
cotrimoxazole is effective, its widespread use byAIDS patients
may have serious adverse consequences for the treatment of
malaria in countries where sulphadoxine-pyrimethamine is
used (18).
The efficacy of primary preventive treatment with
isoniazid to reduce the incidence of TB in HIV-positive
persons, at least in the short to medium term, has been
demonstrated in placebo-controlled studies (19). Secondary
isoniazid preventive therapy in HIV-positive patients who had
completed rifampicin-containing anti-TB treatment signifi-
cantly reduced the risk of recurrent TB in a small study in Haiti
(20). Although there are doubts about the value of isoniazid
preventive therapy as a TB control strategy, it deserves to be
included as part of the package of care offered to HIV-positive
individuals.
Antiretroviral therapy
The greatest improvement in the quality of life and the largest
reduction in death rates amongHIV-positive patients, whether
or not they have TB, is likely to be achieved by HAART. If
HAART is to become more available to people in Africa the
drugs have to be made accessible and an infrastructure has to
be created in order to ensure that they can be administered in a
structured, safe and secure way.
Access to antiretroviral drugs
Pharmaceutical companies have significantly reduced the cost
of antiretrovirals, and drug companies in Brazil, India, and
Thailand are producing cheap generic versions (21). However,
for very poor countries spending less than US$ 5 per capita per
year on health, antiretroviral drugs are still too expensive unless
there is additional assistance.
A meaningful challenge to the AIDS epidemic requires a
huge increase in donor support, not only for antiretrovirals but
also for basic prevention and care packages (22). During 1996–
98, official development assistance for HIV/AIDS in sub-
Saharan Africa was approximately US$ 130 million per year, a
funding level totally incommensurate with the severity of the
AIDS epidemic. A strong case has been made for a global
annual budget of US$ 7.5 billion in the form of grants in order
to support HAART and palliative treatment (22).
In July 2001 the Global Fund to Fight AIDS,
Tuberculosis and Malaria was established in order to support
research into these conditions and their prevention and
treatment (23). The United Nations has calculated that up to
US$ 10 billion are needed annually to fight AIDS alone.
Administration of antiretroviral drugs
Antiretroviral drugs must be provided within a structured
framework. The structure used to deliver and monitor anti-TB
treatment to TB patients throughout the developing world
could be a model for delivering antiretroviral therapy (24). The
overall objective would be to reduce mortality, morbidity, and
the transmission of HIV. Standardized combination antire-
troviral therapy would be used for HIV-positive patients with
symptoms. Targets for antiretroviral therapy would have to be
developed: they might include lifelong treatment and high
drug-adherence rates to minimize the development of drug
resistance. There would be an antiretroviral policy package,
with five key elements (Box 4), similar to that adopted for TB
control. An important aspect of proper casemanagement is the
supervised administration of tablets, i.e. directly observed
therapy, in order to ensure that patients adhere to the regimen.
This is vital if individual benefit is to be maximized and drug
resistance is to be forestalled. In an impoverished community
in rural Haiti, directly observed HAART was effective as part
of a package of care for a small number of patients with AIDS
(25). This supported the view that HAART could be delivered
within the setting of a minimum health infrastructure.
Such a programme could not be implemented country-
wide all at once. A phased approach would be necessary. A
preparatory phase would establish the infrastructure necessary
for the administration of HAART. This might include:
management and coordination structures; HIV/AIDS clinics
and laboratory support facilities; recording, reporting, and
training materials; systems for drug procurement, distribution,
and security; and plans for supervision.
Box 2. Negative effects of human immunodeficiency virus
infection on tuberculosis (TB) control
The negative effects include:
. increased case numbers;
. the need for more staff and resources;
. overcrowding on TB wards because of increased case numbers;
. increased morbidity and adverse drug reactions;
. increased mortality;
. increased rates of recurrence of TB;
. poor delivery of health care.
Box 3. Additional interventions to control tuberculosis (TB)
and human immunodeficiency virus (HIV) infection
. Active case-finding where high rates of TB transmission occur.
. Voluntary counselling and HIV testing.
. Comprehensive care for HIV/AIDS (acquired immunodeficiency
syndrome) with two-way referral systems between health services
and the community.
. Isoniazid preventive therapy (primary and secondary) for HIV-positive
people.
. Adjunctive treatments to reduce morbidity and mortality: cotrimox-
azole prophylaxis and antiretroviral therapy.
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In the second phase, there would be rigorous piloting of
the chosen triple combination therapy. Intensive clinical and
laboratory monitoring would ensure that the regimen was safe
and well tolerated. The aim would be to define simple and
robust clinical management algorithms for the monitoring of
treatment and complications, because, in most districts of
Africa, laboratory monitoring using CD4+-lymphocyte counts
and the determination of viral loadwould not be feasible.While
this phase was taking place, the third phase, involving feasibility
assessment, would begin. Earmarked districts would be
strengthening their infrastructure so as to provide a package
of care for people living with AIDS. The introduction of
HAART would be conditional on this package of care being in
place and operational. Once districts were ready the feasibility
of managing HIV/AIDS patients using HAART would have
to be tested. If the feasibility studies were successful the
programme could be expanded to become countrywide.
Should antiretroviral therapy be delivered
to AIDS patients through national TB control
programmes?
Arguments for
The proposed programme for delivering HAART is based on a
framework similar to that for TB control. Building on an
established TB control infrastructure would be cost-effective.
National TB control programmes have experience of provid-
ing, monitoring, and supervising the care of patients for long
periods of time and are in a position to develop and implement
a structure within which HAART can be effectively and safely
administered.
As HIV is the main factor responsible for the current
epidemic of TB in Africa, an integrated programme has a
greater chance of affecting the TB burden here than any course
of action undertaken by TB control programmes alone. TB is
the main opportunistic infection resulting from HIV: conse-
quently, many patients would have both conditions. Adverse
drug effects occurring when patients are on both anti-TB
treatment and HAART are best managed in a single
programme. Directly observed therapy in respect of anti-TB
treatment and HAART can be administered by the same
provider. In each country a joint approach would provide a real
focus for collaboration between the national TB programme
and the national AIDS programme.
Arguments against
In a country with a well-established HIV/AIDS epidemic, the
demand for antiretroviral drugs would probably be enormous
and the large additional number of patients would threaten to
overwhelm the services of the TB programme, even if extra
staff and resources were allocated. HIV-positive patients
without TB might be at risk of acquiring TB when undergoing
HAART if they had to join outpatient queues in which there
were both TB patients and suspected cases. Anti-TB treatment
continues for six to eight months, whereas HAART is lifelong.
An antiretroviral programme requires more demanding
logistics. Although rifampicin has a well-known street-market
value for the treatment of conditions other than TB,
antiretroviral drugs can be expected to have an enormous
national and international street value, and rigorous systems of
monitoring drug use would have to be developed in order to
safeguard the drugs from theft and prevent abuse.
A compromise
One way forward is to use the DOTS model and integrate the
delivery of HAART into a comprehensive HIV/AIDS
management strategy to complement prevention efforts
already undertaken by AIDS control programmes. The key
entry point to comprehensive HIV/AIDSmanagement would
be voluntary counselling and HIV testing. HIV-positive
patients without TB would receive HAART and have their
treatment monitored at AIDS clinics. If adequate human
resources were available, HIV-positive patients with TB could
be treated by national TB programmes, which could also take
responsibility for the management of antiretroviral therapy
during the course of anti-TB treatment. This would obviate the
need for TB patients having to visit different units in order to
obtain anti-TB drugs and HAART. Because rifampicin
interacts with protease inhibitors and non-nucleoside reverse
transcriptase inhibitors (26), special attention would have to be
paid to the antiretroviral regimen during anti-TB treatment. It
would be necessary to train the staff on TB programmes to
manage the most appropriate antiretroviral regimens for the
initial and continuation phase of anti-TB treatment. Once anti-
TB treatment had been completed the patient could return to
the main antiretroviral drug monitoring system.
In any of these approaches there might be reluctance by
donors to support what appeared to be another vertical
disease programme at a time when thinking on health delivery
in Africa hinges on health sector reform. It would be essential
for staff on AIDS and TB control programmes to work
closely with health planners in order to ensure that core
activities such as regular drug supplies, supervision, monitor-
ing, and recording were maintained and that they continued
uninterruptedly.
Box 4. Antiretroviral policy package
The package would contain the following components:
1. Sustained government and political commitment:
– nationwide coverage of the service
– central, regional, and district units
– full integration of the service into the health system at all levels
– antiretroviral drugs as part of an essential packet of care for HIV/
AIDS (human immunodeficiency virus/acquired immunodeficiency
syndrome) patients.
2. Case detection through passive case-finding, ensuring access to
high-quality voluntary counselling and HIV testing:
– focus should be on HIV-positive patients with symptoms who
have undergone voluntary counselling and HIV testing (e.g. those
fulfilling WHO’s case definition for AIDS in Africa).
3. Administration of standardized antiretroviral regimens under proper
conditions of case management, including direct observation of
therapy:
– Choice of drugs depends on simplicity, efficacy, cost, and safety;
– once-a-day administration is preferable;
– protease inhibitors are best avoided because of interactions with
rifampicin;
– first-line and second-line regimens are required in case of adverse
effects and development of drug resistance.
4. An uninterrupted supply of drugs of assured high quality, with
reliable drug procurement and distribution systems.
5. A recording and reporting system permitting assessment of the
outcome of each patient and of overall programme performance.
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Conclusion
Whether HAART becomes part of the package of care for
HIV-positive patients in sub-Saharan Africa depends on the
support and commitment of the international community,
because countries with very limited resources would be
unable to support an antiretroviral programme, notwithstand-
ing large reductions in drug costs. Also critical is the success
or otherwise of phased studies on effectiveness and feasibility.
The challenges are considerable, but given the scale of the
epidemic, the first steps should be taken as soon as
possible. n
Conflicts of interest: none declared.
Re´sume´
Traitement antire´troviral et lutte antituberculeuse en Afrique : synergies et potentiel
Le VIH/SIDA (virus de l’immunode´ficience humaine/syndrome
d’immunode´ficience acquise) et la tuberculose figurent parmi les
grandes pande´mies qui se´vissent a` l’e´chelle mondiale, particu-
lie`rement en Afrique subsaharienne. Les efforts de lutte contre le
VIH/SIDA ont e´te´ largement axe´s sur la pre´vention et ont peu
porte´ sur les soins. Les travaux sur la lutte antituberculeuse se
sont quant a` eux concentre´s sur la de´tection et le traitement des
cas. L’infection par le VIH complique la lutte contre la tuberculose.
Il est peu probable que l’on puisse assister a` un de´clin du nombre
de cas de tuberculose tant qu’on n’aura pas e´labore´ de nouvelles
strate´gies pour lutter simultane´ment contre cette maladie et
contre le VIH. Ces strate´gies devront comporter un de´pistage actif
des cas la` ou` la transmission de la tuberculose est intense, la
fourniture d’un ensemble de soins pour les maladies associe´es au
VIH et l’application d’un traitement antire´troviral efficace. C’est ce
dernier e´le´ment qui devrait avoir le maximum d’impact, mais pour
le rendre plus accessible en Afrique, il faudra mettre les
me´dicaments a` disposition par le biais d’un soutien international
et mettre en place une structure programmatique en vue de leur
administration. Le traitement pourrait eˆtre dispense´ selon une
strate´gie en cinq points appele´e DOTS adopte´e pour la lutte
antituberculeuse. Cependant, il n’est peut-eˆtre pas re´aliste de
charger les programmes de lutte antituberculeuse de ce surcroıˆt
de responsabilite´. Une meilleure approche pourrait consister a`
de´livrer un traitement antire´troviral efficace dans le cadre d’une
strate´gie globale de prise en charge du VIH/SIDA, en comple´ment
du travail de pre´vention de´ja` re´alise´ par les programmes de lutte
contre le SIDA. Les programmes de lutte antituberculeuse
pourraient contribuer au de´veloppement et a` la mise en œuvre
de cette strate´gie.
Resumen
Terapia antirretroviral de gran potencia y lucha contra la tuberculosis en A´frica: sinergias y posibilidades
La infeccio´n por el VIH/SIDA (virus de la inmunodeficiencia humana/
sı´ndrome de inmunodeficiencia adquirida) y la tuberculosis son dos
de las pandemias ma´s graves del mundo, y castigan en especial al
A´frica subsahariana. Los esfuerzos encaminados a combatir el VIH/
SIDA se han centrado en gran parte en la prevencio´n, habie´ndose
prestado poca atencio´n a la asistencia, y las actividades de control
de la tuberculosis se han centrado en la deteccio´n y el tratamiento
de los casos. La infeccio´n por el VIH ha complicado el control de la
tuberculosis. Es improbable que se produzca una disminucio´n del
nu´mero de casos de tuberculosis a menos que se desarrollen otras
estrategias para controlar simulta´neamente esta enfermedad y el
VIH. Esas estrategias incluirı´an la bu´squeda activa de casos en las
situaciones de alta transmisio´n de la tuberculosis, el suministro de
un paquete asistencial para las enfermedades relacionadas con el
VIH, y la aplicacio´n de terapia antirretroviral de gran potencia. Esto
u´ltimo es lo que ma´s impacto podrı´a tener, pero para ampliar el
acceso a ese tratamiento en A´frica los medicamentos se deberı´an
ofrecer con ayuda internacional, y habrı´a que desarrollar una
estructura de programa para su administracio´n. Podrı´a establecerse
una estructura basada en la estrategia en cinco puntos DOTS
adoptada para combatir la tuberculosis. Sin embargo, la pretensio´n
de delegar en los programas de control de la tuberculosis la
responsabilidad de ejecutar un programa de esa naturaleza es
quiza´ poco realista. Una alternativa preferible consistirı´a tal vez en
el suministro de terapia antirretroviral de gran potencia en el marco
de una estrategia integral de manejo de la infeccio´n por el VIH/SIDA
que complementase las actividades preventivas ya emprendidas
por los programas de control del SIDA. Los programas contra la
tuberculosis podrı´an contribuir al desarrollo y aplicacio´n de esa
estrategia.
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Commentary
TB and HIV: joint problems, joint solutions?
Gijs Elzinga1 & Paul Nunn2
In their article (1), Harries and his colleagues turn the spotlight
on one of the major problems confronting control of
tuberculosis (TB) today. Despite heroic and successful efforts
to establish DOTS programmes in sub-Saharan Africa, TB
continues to rise in countries with significant HIV (human
immunodeficiency virus) epidemics. DOTS alone is insuffi-
cient to prevent such increases. Furthermore, HIV calls into
question the global targets of 85% cure of the 70%of all smear-
positive cases that should present for treatment by the year
2005. These targets were set because their achievement would,
in the absence of other factors, lead to a reduction in TB
incidence. Many working in Africa now believe that control of
TB, especially reduction in its incidence, is dependent upon
mitigating the impact of HIV.What else must we do to control
TB in settings of high HIV prevalence?
From an HIV perspective, it seems probable that two
things are required: a reduction in the number of HIV-infected
people, i.e. a decrease in the transmission of HIV; and lessening
the immunosuppression caused by HIV in those already
infected. In the absence of a vaccine, we are limited to education
for behaviour change, condom provision to prevent transmis-
sion, treatment of sexually transmitted diseases and, in the
absence of a definitive cure, antiretroviral drugs to lessen the
effects ofHIV. From the TBperspective, the additional possible
approaches are active case-finding and prevention of TB.
Combined approaches at the district level against TB and
HIV were merged in the ProTEST initiative (2), set up by
WHO and partners in the late 1990s. On the part of clients, the
interventions include discovering HIV status through counsel-
ling and testing, using condoms, and modifying sexual
behaviour; on the part of providers, actively looking for cases
of TB among the HIV infected and the provision of isoniazid
preventive therapy to those who are HIV positive, but without
active TB. The impact of all this on risk behaviour and on the
burden of TB awaits the final results from the initiative,
expected within the year.
But a few key national managers in high HIV-prevalence
countries made it clear that the international and local response
to control of TB was simply inadequate to address the
enormous scale of the problem. WHO and the Global
Working Group on TB/HIV then considered options
additional to DOTS in high HIV-prevalence settings (3). A
considerable expansion of the original ProTEST work has
begun in eight African countries (Ethiopia, Kenya, Malawi,
Mozambique, South Africa, the United Republic of Tanzania,
Uganda, andZambia) with the Centers forDisease Control and
Prevention’s Global AIDS Program, the Joint United Nations
Programme on HIV/AIDS, and the United States Agency for
International Development as the main partners. These
projects aim to establish an affordable, cost-effective package
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of joint measures against HIV/AIDS and TB that will reduce
the burden of both diseases more efficiently than separate
approaches. The interventions included are laid out in Box 3 of
the paper by Harries et al. (1), who focus on the thorniest of
them all, namely highly active antiretroviral therapy (HAART).
They put to one side some of the key unknowns, namely,
the impact HAART will have on the transmission of both HIV
and TB, and the development of resistance, and turn to the key
question of howHAART should be delivered. Andwill the HIV
community learn the hard-won lessons of the TB community?
Until just recently, the cost of antiretrovirals relieved
health and development workers of having to think much
about them, but themajor price reductions announced last year
and the establishment of mechanisms to support the
purchasing of these drugs (4), have brought the issue to the
forefront. There is the very real risk that the drugs will be
delivered to systems ill-prepared to receive them and ill-
designed to deliver them (5). Harries and his group are among
the first to point to a solution. In a previous paper (6), they
clearly put forward the idea of using well-performing national
TB programmes to deliver not only anti-TB treatment, but also
antiretrovirals. In this issue of the Bulletin, they are less
absolutist and point to the necessity of a comprehensive HIV/
AIDS management strategy to which TB programmes could
contribute. The central pillar of their thesis is Box 4 which
extrapolates directly from the five-point policy framework for
DOTS (7) to lay out the five essential elements of an
antiretroviral policy package.
From experience with TB, this approach, or one very like
it, would seem logically necessary for an antiretroviral delivery
policy. But is it sufficient? Of course not. Full implementation
of the package can only follow the strategic planning, human
resource investment, and financial support required to provide
and sustain the infrastructure necessary for successful delivery
of HAART, and arguably would need to be the largest
expansion of health services in low-income countries ever
seen. Antiretroviral treatment is a lifelong undertaking. In
order to assuage the doubts surrounding sustainability,
HAART must be embedded in a broader developmental
context such as those currently offered in theHeavily Indebted
Poor Countries Initiative and the World Bank’s poverty
reduction strategies (8). n
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